Nanoparticles used in gene therapy in the future? hmmm

michael barry

Senior Member
Reaction score
12
S-12-B

Nanoparticle-based Targeting of Skin Antigen-

Presenting Cells via Hair Follicles

Speaker: Annika Vogt

Clinical Research Center for Hair and Skin Physiology,

Berlin, Germany

Authors: Annika Vogt1, Brice Mahe2, Wolfram Sterry1,

Behazine Combadiere2, Ulrike Blume-Peytavi1

1 Clinical Research Center for Hair and Skin Physiology,

Department of Dermatology and Allergy, Charite –

Universitaetsmedizin Berlin, Berlin, Germany;

2 Laboratoire d’Immunologie Cellulaire et Tissulaire,

Hôpital Pitié Salpêtrière, INSERM U543, Paris, France

Drug delivery systems, which target active compounds

to the hair follicle, may result in a better penetration and

a higher ef. ciency of hair and skin therapy. Recent studies

performed by our group suggest, that nanoparticles in

the size range of 40 nm may be used to transcutaneously

deliver active vaccine compounds, via the hair follicle, into

cutaneous antigen-speci. c cells. To further investigate

the applicability of transcutaneously applied nanoparticles

as vaccine carriers, we investigated the penetration and

the migratory pro. le of 40 nm nanoparticles through the

skin and to secondary lymphoïd organs of C57BL6 mice

using in vivo confocal microscopy. We found that 40 nm

nanoparticles penetrated deeply into open hair follicles

of tape-stripped murine skin. Within 24 hrs diffusion into

the perifollicular tissue occurred, and, concomitantly,

nanoparticle-positive cells could be identi. ed in proximal

draining lymph nodes, mesenteric lymph nodes and the

spleen. Transcutaneous application of immunogenic

compounds such as DNA plasmids encoding for ovalbumin

(OVA) or OVA itself induced proliferation of OVA-speci. c

CD8 T cells. Similarly, transcutaneously applied human

in. uenza vaccine elicited antigen-speci. c T cells assessed

by IFN ELISPOT. Our results further strengthen our concept

transcutaneous targeting of cutaneous antigen-presenting

cells. Further studies using functional particle-bound

antigens will help to validate this route of immunisation.
 
Top